by Elana Gotkine For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 issue of the New England Journal of Medicine. Robert Bissonnette, M.D., from Innovaderm Research in Montreal, and colleagues conducted a phase 2 dose-finding trial involving 255 patients...